BACKGROUND: Advanced biliary cancer is often treated with fluoropyrimidine-based chemotherapy. In this study, we evaluated the efficacy and tolerability of a combination of S-1, an oral fluoropyrimidine prodrug, and oxaliplatin in patients with metastatic biliary cancer. METHODS: Patients with histologically confirmed metastatic biliary cancer and no history of radiotherapy or chemotherapy were enrolled. Oxaliplatin was administered intravenously (130 mg m
S-1, an oral prodrug of 5-FU composed of tegafur, 5-chloro-2, 4-dihydroxypyridine (CDHP; gimestat), and potassium oxonate (otastat), shows clinical efficacy in patients diagnosed with various solid tumours, including biliary tract cancers Sasaki et al, 2009) . Combinations of S-1 and cisplatin have also yielded modest response rates and tolerable toxicity profiles (Kim et al, 2008b; Kang et al, 2010) .
The pharmacokinetic and toxicity profiles of S-1 differ with ethnicity (Hirata et al, 1999; Hoff et al, 2003; Chu et al, 2004) . The principal dose-limiting toxicities are diarrhoea in Caucasian and myelosuppression in Asian patients (Hirata et al, 1999; Cohen et al, 2002) . These differences may be attributable to genetic variations in CYP2A6 encoding a cytochrome P450 enzyme that has a major role in the biotransformation of tegafur to 5-FU (Ikeda et al, 2000) . One clinical study demonstrated an association of the CYP2A6*4 allele with exposure to 5-FU in non-small-cell lung cancer patients receiving S-1, while another study suggested that exposure to CDHP, which affects the metabolism of 5-FU, is the key determinant of variability in 5-FU efficacy following S-1 administration (Fujita et al, 2008; Kaida et al, 2008) .
The primary objective of the present study was to evaluate the efficacy and safety of S-1 in combination with oxaliplatin chemotherapy in patients with metastatic BTC and objective response rate was the primary endpoint. The secondary objective was to evaluate the relationships between pharmacokinetics, clinical activity and tolerability of S-1-based chemotherapy and CYP2A6 genotypes.
PATIENTS AND METHODS

Eligibility criteria
Patients with histologically confirmed recurrent or metastatic cancer of the biliary tract were eligible, provided that they met the following criteria, including at least one unidimensionally measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) guidelines Version 1.0, age between 18 and 70 years, Eastern Cooperative Oncology Group (ECOG) performance status of 0 -2, adequate haematological (haemoglobin X9.0 g dl À1 , absolute neutrophil count (ANC) X1.5 Â 10 9 l À1 , and platelet count X100 Â 10 9 l À1 ), hepatic (total bilirubin p1.5 mg dl À1 , serum transaminase p3 Â upper normal limit or p5 Â upper normal limit in cases of hepatic metastases), and renal (serum creatinine p1.5 mg dl
À1
) functions, no history of radiation therapy or chemotherapy, including S-1 or oxaliplatin treatment within 6 months, and no history of gastrointestinal operations, including gastrectomy or pancreaticoduodenectomy. Patients were excluded if they had central nervous system metastasis, gastrointestinal obstruction, bleeding or sensory neuropathy greater than grade 2, according to the National Cancer Institute of Common Toxicity Criteria (NCI CTC) Version 3.0. Creatinine clearance was calculated using the Cockcroft-Gault equation (Cockcroft and Gault, 1976) . The protocol was approved by the institutional ethics committee, and all patients provided written informed consent before enrollment. This study was conducted using the Good Clinical Practice guidelines, in accordance with the Declaration of Helsinki and its amendments.
Study design and treatment
This was a single centre phase II study performed to evaluate the efficacy and safety of the S-1 and oxaliplatin combination therapy. S-1 was administered orally at a dose of 40 mg m À2 twice daily for 14 days, followed by a 7-day rest period. S-1 doses were calculated in milligrams per square metre of body surface area, and rounded down to the nearest 5 or 10 mg. For pharmacokinetic analysis, S-1 was given only once on day 1 of cycle 1. Beginning on day 2, S-1 was administered twice daily. Oxaliplatin was administered intravenously at 130 mg m À2 for 2 h on day 2 of cycle 1, and day 1 of cycle 2 and subsequent cycles. Treatment was repeated every 21 days, and continued for a maximum of 9 cycles in the absence of progressive disease, development of unacceptable toxicity, or patient refusal.
Doses of S-1 and oxaliplatin were reduced based on the extent of haematologic and non-hematologic toxicities evaluated before each treatment cycle, according to NCI CTC toxicity scale Version 3.0. At the first occurrence of grade 3 thrombocytopenia or grade 4 neutropenia lasting o5 days, S-1 treatment was interrupted, but was resumed at the same dose after resolution to grade 1 or better. At the second or third occurrence of the same haematologic toxicity with similar severity, treatment was interrupted, followed by 25 or 50% dose reduction of S-1 and oxaliplatin (to 100 and 85 mg m À2 , respectively) in subsequent cycles. If the haematologic toxicity recurred with similar severity after adequate dose reduction, treatment was discontinued. In cases of grade 3 or 4 non-hematologic toxicity, treatment was interrupted, followed by a 25 or 50% dose reduction, respectively. The oxaliplatin dose was modified in cases where patients developed grade 2 neurosensory toxicity. Treatment was interrupted until toxicity resolved to grade 1 or better, with reduction of the oxaliplatin dose to 100 mg m À2 in subsequent cycles. In patients experiencing a second occurrence of grade 2 neurosensory toxicity, treatment was interrupted, and the oxaliplatin dose reduced to 85 mg m À2 . Treatment was discontinued if patients experienced recurrence of grade 2 neurosensory toxicity after two oxaliplatin dose reductions, if oxaliplatin therapy was delayed for 42 weeks because of toxicity, or if patients developed grade 3 or higher neurosensory toxicity.
Efficacy and safety assessments
All patients who received at least one cycle of treatment were subjected to efficacy and safety assessments. Response rate, the primary endpoint, was evaluated according to the Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.0 (Therasse et al, 2000) . Evaluation of tumours was performed every two cycles. Chemotherapy was discontinued in cases of disease progression, unacceptable toxicity or withdrawal of consent. Adverse drug reactions were graded according to National Cancer Institute Common Toxicity Criteria Version 3.0.
Pharmacokinetic assay
Blood samples (about 10 ml) were collected in heparinised tubes at 0.5, 1, 2, 4, 8, 12, and 24 h after the first single dosage of S-1 administered during cycle 1. Tubes were centrifuged (3500 r.p.m., 8 min, 41C), and plasma immediately separated and transferred as three aliquots into storage cryotubes, which were frozen at À801C until analysis. Plasma concentrations of all compounds were determined using liquid chromatographic -tandem mass spectrometry. Tegafur, FU, and CDHP were analysed on the API 3000 LC/MS/MS system (MDS Sciex, Concord, Ontario, Canada). Plasma concentration data were used to calculate pharmacokinetic parameters, including area under the curve from 0 to 24 h (AUC 0À24 h ) and maximum concentration (C max ), by the linear trapezoid method using WinNonlin (Professional Network Version 5.2; Pharsight Corporation, Mountain View, CA, USA).
CYP2A6 genotyping assay
Genomic DNA was extracted from whole blood using a specific DNA preparation kit (QIAamp Blood Mini Kit; Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. Genotypes of CYP2A6*1, *7, *9 and *10 allelic variants were determined using the multiplex minisequencing (SNaPshot, ABI PRISM SNaPshot Multiplex Kit; Applied Biosystems, Foster City, CA, USA) method. Briefly, the full-length CYP2A6 gene was amplified using a pair of primers, specifically, 5 0 -CTCTCCCCTGGAACCCC CAG-3 0 and 5 0 -GCACTTATGTTTTGTGAGACATCAGAGACAA-3 0 . PCR was performed on a 9700 thermal cycler (PE Applied Biosystems, Foster city, CA, USA) under the following conditions: initial denaturation at 941C for 1 min, followed by 30 cycles of 981C for 20 s, 641C for 30 s, 721C for 3 min 30 s, and a final elongation step at 721C for 10 min. The 7.5 kb PCR product was used as a template for the SNaPshot reaction, which contained the following sequencing primers: CYP2A6-48T4G (*9), 5 0 -GGCTGGGGTGG TTTGCCTTT-3 0 ; CYP2A6 6600G4T (*10), 5 0 -GGAAGCTCA TGGTGTAGTTT-3 0 ; and CYP2A6 6558T4G (*7), 5 0 -CTCCCAGTC ACCTAAGGACA-3 0 . Genotype analyses were performed with GeneMapper (Version 3.7) software (Applied Biosystems). For genotyping the CYP2A6 deletion allele (*4), allele-specific amplification and restriction fragment length polymorphism analysis were performed, as described previously (Nakajima et al, 2001 ).
Statistical analyses
Standard descriptive and analytical methods were used to describe the patient population and their baseline characteristics. This trial was designed using Fleming's single-stage Phase II procedure to test the null hypothesis that the true objective response rate was o15%, with a sample size sufficient to reject it when the true objective response rate was 435% with an 80% power and using a level of a ¼ 5% (one-sided test), and required a sample size of 44 patients (Machin et al, 1997; Kim et al, 2008b) . We assumed a dropout rate of 10%, making the required number of patients 49.
To analyse the effects of CYP2A6 genotypes, the pharmacokinetic parameters of S-1 were log-transformed and compared using mixed model analysis of variance (ANOVA). To evaluate CYP2A6 genotype-drug interactions, the differences in log-transformed mean values between wild type (*1/*1) and variants (single or double) were calculated, and both point estimates and 90% confidence interval (CI) back-transformed to obtain geometric mean ratios, along with CI values for the ratios. Progression-free survival (PFS) was calculated from the commencement of chemotherapy to date of disease progression or death from any cause, and overall survival (OS) calculated from the start of chemotherapy to date of death from any cause. Survival analyses were performed using the Kaplan-Meier method with the log-rank test. Data analyses were performed using the Statistical Software Package for Social Sciences (SPSS version 14.0; Chicago, IL, USA).
RESULTS
Patient characteristics
From September 2006 to January 2008, we enrolled a total of 49 patients with histologically confirmed recurrent or metastatic adenocarcinoma of the biliary tract (Table 1) . No patient had previously received radiation therapy or chemotherapy, including S-1 or oxaliplatin. Median patient age was 52 years (range, 23 -68 years), and 31 patients (63%) were male. Most patients (94%) showed good performance status with ECOG scale values of 0 -1. All patients had good renal function, and mean creatinine clearance was 97.40 ml min À1 (range, 57.13 -198.0 ml min À1 ). A total of 30 patients (61%) were diagnosed with intrahepatic cholangiocarcinoma, and 10 (20%) with gallbladder cancer. In all, 40 patients (82%) had metastatic abdominal lymphadenopathy, with the liver being the most common metastatic organ (67%).
Efficacy
Among the 49 study patients, 45 were evaluated for response. The remaining four subjects were lost to follow-up and hence were not assessable. Partial response was observed in 24.5% (12 out of 49) and stable disease in 34.7% (17 out of 49) of patients. The overall response rate in the intention-to-treat population was 24.5% (95% (CI), 12.5 -36.5%; Table 2 ). Patients with gallbladder cancer tended to show a higher response rate than those with intra-or extra-hepatic cholangiocarcinoma, but the difference was not statistically significant. At a median follow-up duration of 20 months (range, 9.4 -25.6 months), median PFS and OS for all patients were 3.7 months (95% CI: 1.7 -5.7 months) and 8.7 months (95% CI: 4.8 -12.6 months), respectively ( Figure 1 ). We observed no significant survival differences with respect to tumour location (data not shown).
Drug exposure and safety
The 49 patients underwent a total of 216 treatment cycles (median, 4 cycles), 212 of which were assessable for toxicity. The frequencies of haematological and non-haematological toxicities are summarised in Table 3 . The most common (45%) grade 3 out of 4 haematological toxicity was neutropenia with an incidence of 12% (6 out of 49). However, no febrile neutropenia was observed. The most common non-hematological grade 3 out of 4 toxicity was anorexia (7 out of 49, 14%), followed by nausea (6 out of 49, 12%), Relationships among pharmacokinetic parameters, clinical efficacy, toxicity of S-1, and CYP2A6 genotypes CYP2A6 genotypes were analysed in all 49 patients, and full pharmacokinetic data were obtained for 48 of the patients. Wildtype homozygotes (CYP2A6*1/*1) were detected in 14 patients, and In 48 patients, the 5-FU level reached peak plasma concentrations (C max ) about 4 h after administration of S-1. The pharmacokinetic parameters are presented in Table 4 . Plasma concentrations of 5-FU tended to be higher in the CYP2A6 *1 homozygotes than patients with variant gene types (Figure 2) . Specifically, C max, 5ÀFU and AUC 0À24 h, 5ÀFU for CYP2A6 variant types were 70% (90% CI: 55 -88%) and 74% (90% CI: 56 -98%) those for *1 homozygotes (Table 4) . On the other hand, FT plasma concentrations were lower in the CYP2A6 *1 homozygotes, compared with those in patients with genetic variations (Figure 2) ; The C max,FT and AUC 0À24 h,FT values for CYP2A6 *1 homozygotes were 17% (90% CI: 2 -33%) and 37% (90% CI: 19 -58%) higher than those with variant genes (Table 4) . CDHP plasma concentrations were similar in both groups.
The ratio between exposure to 5-FU and FT (AUC 0À24 h of 5-FU/ AUC 0À24 h of FT) was 0.0710±0.0433 in the wild-type group and 0.0331 ± 0.0160 in patients with single or double variants (Table 4, Figure 3) , yielding a 1.85-fold higher metabolic ratio (90% CI: 1.37 -2.49) in the wild-type group. However, comparison of the frequencies of diarrhoea and neutropenia between wild type and variants revealed that the CYP2A6 *1/*1 genotype was not significantly associated with any grade of diarrhoea (wild type, 5 out of 13, vs variant type, 7 out of 35; P ¼ 0.0740) or neutropenia (wild type, 4 out of 13, vs variant type, 7 out of 35; P ¼ 0.396). In addition, exposure to 5-FU (AUC 0À24 h, 5ÀFU ) was not significantly correlated with severity of diarrhoea or neutropenia (Figure 4) .
DISCUSSION
This study evaluated the efficacy and safety of S-1 and oxaliplatin in Korean patients with metastatic biliary tract carcinoma. The response rate was 24.5%, and median PFS and OS were 3.7 and 8.7 months, respectively, similar to results obtained from trials of S-1 combinations with cisplatin and oxaliplatin (Kim et al, 2008b; Oh et al, 2008) . The frequencies of diarrhoea (4%) and neutropenia (14%) exceeding grade 3 were comparable with those of other studies, which used similar dosages of S-1 and oxaliplatin (Yamada et al, 2008; Zang et al, 2009) .
Recently, survival gain in biliary tract cancers with gemcitabinebased chemotherapy was reported. Moreover, a combination of gemcitabine and cisplatin displayed benefits over gemcitabine monotherapy in a randomised, phase III trial (Valle et al, 2010) . A small-scale randomised phase II trial showed that survival rates with gemcitabine and oxaliplatin surpassed those with fluorouracil and folinic acid in unresectable gall bladder cancer (Sharma et al, 2010) . On the other hand, several phase II trials have supported the utility of 5-FU-based containing regimens for biliary tract cancers (Eckel and Schmid, 2007) . Although gemcitabine-based chemotherapy may be the preferred treatment based on recent phase III Figure 1 Kaplan -Meier curves of progression-free survival (PFS) and overall survival (OS) for all 49 patients. Median PFS and OS were 3.7 months (95% CI: 1.7 -5.7 months) and 8.7 months (95% CI: 4.8 -12.6 months). Influence of the CYP2A6 polymorphism K-p Kim et al trials, it is not evident whether gemcitabine surpasses fluoropyrimidine in terms of efficacy (Kim et al, 2008a) . Combination chemotherapy consisting of gemcitabine, 5-FU derivatives and platinum analogue regimens led to response rates between 20 and 30% and median survival of 8 -12 months (Verslype et al, 2008) . The recorded overall response of 24.5% meant that our study did not meet its primary endpoint response rate of 35%. However, some biologic features of biliary tract cancers should be considered. First, response rates and survival differ significantly according to the primary site of the tumour, and intrahepatic cholangiocarcinoma has the worst prognosis ). The proportion of intrahepatic cholangiocarcinoma was substantially higher than expected (61%), which may have influenced the overall response rate. Second, many studies have used tumour control rate (defined as stable disease, complete or partial response) to assess efficacy owing to the aggressive nature of advanced biliary tract cancer. We recorded a tumour control rate of 59.2%, which is comparable with data from previous studies with S-1 and cisplatin (Kim et al, 2008b) . Third, we recently showed that gemcitabine was better than S-1 as a doublet partner for platinum agents in advanced biliary cancers (Kang et al, 2010) . However, gemcitabine was associated with higher toxicities, especially neutropenia and thrombocytopenia. As fluoropyrimidine-based chemotherapy induces lower haematological toxicities and decreased tendency of biliary tract cancer-related infections, including cholangitis and liver abscess, S-1 use may be favored in a subset of patients (Kim et al, 2008a) . Moreover, S-1 offers the convenience of oral administration, in contrast to the weekly intravenous administration of gemcitabine. Therefore, well-designed randomised phase III trials are required to compare fluoropyrimidine plus platinum combination with gemcitabine plus platinum combination chemotherapy in terms of efficacy and safety.
Despite these advantages, S-1 pharmacokinetics is subject to interindividual variability, which is explained by the pharmacogenetics of CYP2A6 (Goh et al, 2008) . The variant genotypes of CYP2A6 display decreased baseline enzyme activity, leading to reduced 5-FU formation. We categorised pharmacokinetic parameters as 'wild type' (*1/*1) and 'variant type' (single and double variant) genotypes, consistent with pharmacogenetic studies on nicotine, another substrate of CYP2A6 (Schoedel et al, 2004; Nakajima et al, 2006; Mwenifumbo et al, 2007) . On comparing the ratio between AUC 0À24 h of 5-FU and AUC 0À24 h of FT by CYP2A6 genotype, this ratio was 1.85-fold greater in the*1/*1 group than the variant-type group. A previous study reported that non-small cell lung cancer patients with CYP2A6*4 alleles, which complete lack relevant enzymatic activity, show significantly lower plasma concentrations of 5-FU (Kaida et al, 2008) . In addition to CYP2A6*4 alleles, CYP2A6*7, *9, and *10 displayed decreased enzyme activity. Our present observations have expanded the application of CYP2A6 genotyping by including various alleles in the interpretation of S-1 pharmacokinetics.
Despite differences in exposure, the CYP2A6 genotype was not significantly associated with clinical efficacy or incidence of toxicity, suggesting that the pharmacokinetic-pharmacodynamic relationships of 5-FU are complicated. Studies using various schedules and formulations of 5-FU have reported a correlation between exposure to 5-FU and toxicity, particularly diarrhoea (Cohen et al, 2002; Chu et al, 2004; Ajani et al, 2005; Gusella et al, 2006; Gamelin et al, 2008) . Conversely, other studies have been unable to establish an association between the AUC of 5-FU and toxicity after S-1 administration (Hirata et al, 1999) . This lack of association may also be attributed to the other constituents of S-1. The action of oxonate, which inhibits the orotate phosphoribosyl-transferase (OPRT) enzyme in intestinal tissue and decreases the occurrence of diarrhoea, may be related to interindividual differences (Shirasaka et al, 1993; Peters et al, 2003) . The clinical efficacy of fluoropyrimidines, including S-1, is influenced by thymidylate synthase, which may confound the association between 5-FU exposure and clinical efficacy (Ichikawa et al, 2004) . A recent investigation reported a correlation between the CYP2A6 genotype and efficacy of S-1-based chemotherapy in advanced gastric cancer (Kong et al, 2009 ). However, pharmacokinetic data for clarifying the exposure-effect relationship were not evaluated.
S-1 is mainly used in Korea and Japan, whereas capecitabine is often used in Western countries. In a study on the efficacy of capecitabine and oxaliplatin in advanced biliary tract cancers, Nehls et al (2008) observed a tumour control rate of 77%, which is higher than that obtained in our study. However, it must be noted that patient characteristics between the two studies differed, since we analysed more cases of intrahepatic cholangiocarcinoma, which has the worst prognosis among the biliary tract cancers. An additional finding is that the recommended dose of S-1 for Asians is higher than that for Caucasians (Hoff et al, 2003) . This has been explained by the fact that Caucasians show a higher frequency of wild-type CYP2A6 and suffer from gastrointestinal toxicities. Another Korean group recently reported adequate efficacy and safety with 50 mg m À2 S-1 twice a day in combination with 130 mg m À2 oxaliplatin for colorectal cancer ).
In conclusion, the present results suggest that a combination of S-1 and oxaliplatin is active and safe for patients with advanced biliary tract cancer. At present, gemcitabine is favored as the backbone for chemotherapy in biliary tract cancers, based on efficacy studies. However, an oral 5-FU based regimen, such as capecitabine or S-1, may be preferable in terms of convenience. Large-scale studies are required to properly address this issue. Our findings further indicate that differences in the CYP2A6 genotype may affect individual pharmacokinetics of S-1, but do not have a significant impact on clinical efficacy or toxicity. * 1 / * 1 * 1 / * 1 0 * 1 / * 1 5 * 1 / * 4 * 1 / * 7 CYP2A6 genotype * 1 / * 9 * 4 / * 9 * 7 / * 1 0 * 7 / * 9 * 9 / * 9 Figure 3 Comparison of metabolic ratios based on type of CYP2A6 polymorphism in 48 patients treated with S-1 and oxaliplatin. Genotypes were categorised according to the number of variant (non-wild type) alleles. 
